Use of Intravenous immunoglobulins for Alzeheimer's disease including Mild Cognitive Impairment (Core HTA 2)

U EUnetHTA JA2, WP4, Služba za razvoj, istraživanje i zdravstvene tehnologije aktivno je sudjelovala kao jedan od autora u međunarodnoj procjeni intravenske primjene imunoglobulina u bolesnika s blagim kognitivnim oštećenjem i Alzheimer-ovom bolesti.
Dokument završne procjene “Use of Intravenous immunoglobulins for Alzeheimer's disease including Mild Cognitive Impairment (Core HTA 2), nalazi se na EUnetHTA web stranicama, http://www.eunethta.eu/joint-assessments; http://www.eunethta.eu/outputs/use-intravenous-immunoglobulins-alzeheimers-disease-including-mild-cognitive-impairment-core; http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Intravenous%20immunoglobulins%20for%20Alzheimer%27s%20disease_Core%20HTA%202_Final_Nov%202015.pdf; http://meka.thl.fi/htacore/ViewCover.aspx?id=267.